The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...

– Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with ...

Agios Pharma’s oral PK activator, Aqvesme receives US FDA approval to treat anaemia in adults with alpha- or beta-thalassemia: Cambridge, Massachusetts Friday, December 26, 2025 ...

Agios Pharmaceuticals announced that it will present new data on its pyruvate kinase activators, mitapivat and tebapivat, during the 30th European Hematology Association (EHA) Congress in Milan from ...

Safety Results Consistent with Safety Profile for Mitapivat Previously Observed in Adults with PK Deficiency Who are Regularly Transfused – – Prespecified Statistical Criterion for the Primary ...

Agios Pharmaceuticals (AGIO) “announced that the U.S. Food and Drug Administration has approved AQVESME, or mitapivat, an oral pyruvate kinase ...

Agios Pharmaceuticals, Inc. will host a conference call and live webcast on February 13, 2025, at 8:00 a.m. ET to discuss its fourth-quarter and full-year 2024 financial results and business ...